TD Asset Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-372,146
| Closed | -$8.12M | – | 1463 |
|
|
2023
Q3 | $8.12M | Buy |
372,146
+168,697
| +83% | +$3.68M | 0.01% | 624 |
|
|
2023
Q2 | $6.47M | Buy |
203,449
+22,226
| +12% | +$707K | 0.01% | 685 |
|
|
2023
Q1 | $4.42M | Sell |
181,223
-4,321
| -2% | -$105K | 0.01% | 776 |
|
|
2022
Q4 | $5.85M | Hold |
185,544
| – | – | 0.01% | 704 |
|
|
2022
Q3 | $5.17M | Buy |
185,544
+2,536
| +1% | +$70.7K | 0.01% | 744 |
|
|
2022
Q2 | $4.84M | Sell |
183,008
-12,800
| -7% | -$338K | 0.01% | 781 |
|
|
2022
Q1 | $6.86M | Sell |
195,808
-20,300
| -9% | -$711K | 0.01% | 751 |
|
|
2021
Q4 | $7.01M | Buy |
216,108
+41,632
| +24% | +$1.35M | 0.01% | 773 |
|
|
2021
Q3 | $5.15M | Buy |
174,476
+19,886
| +13% | +$587K | 0.01% | 808 |
|
|
2021
Q2 | $3.81M | Buy |
154,590
+39,875
| +35% | +$982K | ﹤0.01% | 909 |
|
|
2021
Q1 | $1.58M | Buy |
114,715
+77,557
| +209% | +$1.06M | ﹤0.01% | 1163 |
|
|
2020
Q4 | $616K | Buy |
+37,158
| New | +$616K | ﹤0.01% | 1291 |
|